Aytu BioPharma, Inc.
AYTU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.00 | 0.00 | -0.04 |
| FCF Yield | -3.48% | 18.82% | -88.62% | 27.81% |
| EV / EBITDA | -3.97 | -0.39 | 1.94 | 2.72 |
| Quality | ||||
| ROIC | -2.47% | -10.80% | 3.82% | -5.07% |
| Gross Margin | 66.14% | 67.75% | 69.40% | 66.49% |
| Cash Conversion Ratio | -0.31 | -0.14 | -1.62 | 3.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -13.25% | -14.82% | -12.72% | -15.02% |
| Free Cash Flow Growth | -122.18% | 142.70% | -325.04% | 318.63% |
| Safety | ||||
| Net Debt / EBITDA | -9.37 | 0.46 | 0.72 | -1.24 |
| Interest Coverage | -2.91 | -10.44 | 2.69 | -1.57 |
| Efficiency | ||||
| Inventory Turnover | 0.47 | 0.43 | 0.51 | 0.49 |
| Cash Conversion Cycle | 172.40 | 200.62 | 159.07 | 130.78 |